Network meta-analysis for efficacy and safety of aromatase inhibitors for postmenopausal hormone receptor-positive early breast cancer
- VernacularTitle:芳香化酶抑制剂用于绝经后激素受体阳性早期乳腺癌有效性及安全性的网状Meta分析
- Author:
Yujie LI
1
;
Wenjing ZHANG
2
;
Hongxin YANG
3
;
Hao GUO
2
Author Information
1. Dept. of Pharmacy，Inner Mongolia Autonomous Region People’s Hospital，Hohhot 010017，China;School of Pharmacy，Baotou Medical College，Inner Mongolia Baotou 014040，China
2. Dept. of Pharmacy，Inner Mongolia Autonomous Region People’s Hospital，Hohhot 010017，China
3. Dept. of Pharmacy，Inner Mongolia Autonomous Region People’s Hospital，Hohhot 010017，China;Inner Mongolia Autonomous Region Essential Drug Monitoring and Clinical Comprehensive Evaluation Center，Hohhot 010017，China
- Publication Type:Journal Article
- Keywords:
aromatase inhibitors;
exemestane;
anastrozole
- From:
China Pharmacy
2025;36(12):1520-1524
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of three aromatase inhibitors （exemestane， anastrozole， letrozole） for postmenopausal hormone receptor （HR）-positive early breast cancer. METHODS PubMed， the Cochrane Library， Embase， CNKI， Wanfang Data， VIP and SinoMed were searched to collect randomized controlled trials （RCTs） of the above three drugs in the treatment of postmenopausal HR-positive early breast cancer patients. The retrieval time limit was from the establishment of the database to October 25， 2024. After literature screening， data extraction and literature quality evaluation， network meta-analysis was performed by using RevMan 5.3 and Stata 18.0 software. RESULTS A total of 15 RCTs involving 44 055 patients were included. The results of network meta-analysis showed that the objective response rate of letrozole group was significantly higher than anastrozole group （P＜0.05）， and the order of surface under the cumulative ranking curve （SUCRA） from high to low was letrozole （85.6%）＞anastrozole （61.5%）＞exemestane （2.8%）. The disease-free survival rate of anastrozole group was significantly higher than exemestane and placebo groups （P＜0.05）， and the order of SUCRA from high to low was letrozole （85.8%）＞ anastrozole （67.3%）＞exemestane （41.4%）＞placebo （5.5%）. The total incidence of adverse reactions in anastrozole group was significantly higher than letrozole and placebo groups （P＜0.05）， and the order of SUCRA from high to low was exemestane （87.4%）＞letrozole （63.9%）＞anastrozole （47.0%）＞placebo （1.7%）. The results of subgroup analysis according to the course of treatment≥104 weeks were consistent with them. CONCLUSIONS Compared with anastrozole， letrozole has better efficacy and safety in the treatment of postmenopausal HR-positive early breast cancer， and the efficacy of exemestane is limited.
